Government support is fueling expansion in the Rare Kidney Diseases Market 2026

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

How Large Is The Rare Kidney Diseases Market Projected To Become By 2030 Based On Its 2026 Valuation?

The rare kidney diseases market size has experienced robust growth in recent years. It is anticipated to expand from $3.03 billion in 2025 to $3.32 billion in 2026, achieving a compound annual growth rate (CAGR) of 9.5%. This historical growth can be attributed to factors such as restricted treatment options for rare renal disorders, increasing awareness of genetic kidney diseases, a rising prevalence of autoimmune-related nephropathies, the expansion of nephrology specialty care centers, and the early adoption of immunosuppressive therapies.

The rare kidney diseases market size is projected for substantial expansion over the next few years. It is forecast to grow to $4.88 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 10.2%. This growth during the forecast period is attributable to advancements in genomics-based drug discovery, a rise in orphan drug approvals, increasing investment in rare disease research, the growing adoption of personalized medicine approaches, and an expanding pipeline of complement and immune-targeted therapies. Major trends expected in this period include a rising focus on targeted therapies for rare renal disorders, increasing clinical trial activity for orphan kidney drugs, a growing adoption of biologics in immune-mediated kidney diseases, the expansion of companion diagnostics for early disease detection, and increasing regulatory incentives for rare disease drug development.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=11908&type=smp

Which Market Drivers Are Supporting The Expansion Of The Rare Kidney Diseases Market?

The growing occurrence of chronic kidney disease (CKD) significantly contributes to the rare kidney disease market. Chronic kidney disease is a condition where the kidneys are damaged and cannot properly filter blood. The higher prevalence of chronic kidney diseases will increase the chances of patients developing rare kidney diseases, which will in turn raise the demand for therapeutics needed for these conditions. For instance, in August 2025, according to the National Kidney Foundation, Inc., a US-based voluntary nonprofit health organization, the Senate approved an increase of $5 million in the FY 2026 Labor, Health and Human Services, and Education appropriations bill to support kidney transplant reform and early detection initiatives. This funding boost elevates the total for the Organ Procurement and Transplantation Network (OPTN) Modernization Initiative to $59 million. Therefore, the increasing prevalence of chronic kidney disease (CKD) will drive the rare kidney disease market.

What Segment Groups Are Identified Within The Rare Kidney Diseases Market?

The rare kidney diseases market covered in this report is segmented –

1) By Target Indication: IgA Nephropathy, Lupus Nephritis, Focal Segmental Glomerular Sclerosis, Membranous Nephropathy, C3 Glomerulopathy, Other Target Indications

2) By Type Of Molecule: Small Molecules, Biologics

3) By Route Of administration: Oral, Intravenous, Subcutaneous, Other Routes Of Administration

Subsegments:

1) By IgA Nephropathy: Immunosuppressive Therapy, Supportive Care And Symptomatic Management

2) By Lupus Nephritis: Corticosteroids, Antimalarial Agents, Biologics

3) By Focal Segmental Glomerular Sclerosis (FSGS): Corticosteroids, Angiotensin Receptor Blockers (ARBs), Other Immunosuppressive Agents

4) By Membranous Nephropathy: Corticosteroids, Immunosuppressive Therapy, Monoclonal Antibodies

5) By C3 Glomerulopathy: Complement Inhibitors, Supportive Care, Immunosuppressive Therapies

6) By Other Target Indications: Alport Syndrome, Thin Basement Membrane Nephropathy, Other Rare Kidney Disorders

What Trends Are Advancing Progress In The Rare Kidney Diseases Market?

Leading companies in the rare kidney diseases market are increasingly concentrating on the development of non-immunosuppressive therapies for these conditions. This innovative treatment approach offers a unique capability to address progressive kidney diseases, a feat not achievable with conventional therapies currently used for rare kidney disorders. For example, in February 2023, Travere Therapeutics, a biopharmaceutical company based in the US, introduced sparsentan, commercially known as Filspari. This medication stands as the first non-immunosuppressive therapy to receive approval for primary immunoglobulin A nephropathy (IgAN). Operating through a distinct mechanism, Filspari works by blocking angiotensin and endothelin receptors. This particular characteristic distinguishes Filspari from angiotensin-targeting ACE inhibitors and ARBs; these are well-established drugs primarily prescribed for hypertension but have been repurposed for IgAN treatment due to their ability to reduce kidney blood pressure.

Which Companies Hold Significant Positions In The Rare Kidney Diseases Market?

Major companies operating in the rare kidney diseases market are Merck & Co. Inc., Novartis AG, Sanofi S.A, AstraZeneca plc, Otsuka Pharmaceutical Co Ltd., Alexion Pharmaceuticals Inc., Horizon Therapeutics plc., Recordati S.p.A., Amicus Therapeutics Inc., Akebia Therapeutics Inc., Travere Therapeutics, FibroGen Inc., Aurinia Pharmaceuticals Inc., Calliditas Therapeutics AB, Apellis Pharmaceuticals Inc., Protalix Biotherapeutics Inc., ChemoCentryx Inc., Omeros Corporation, Celtaxsys Inc., Corbus Pharmaceuticals Holdings Inc., Chinook Therapeutics Inc., OxThera AB, Advicenne Pharma SA, Reata Pharmaceuticals Inc.

Read the full rare kidney diseases market report here:

https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

How Is The Rare Kidney Diseases Market Distributed Across Key Geographic Regions?

North America was the leading region in the rare kidney disease market in 2025. The regions covered in the rare kidney diseases market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Rare Kidney Diseases Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=11908&type=smp

Browse Through More Reports Similar to the Global Rare Kidney Diseases Market 2026, By The Business Research Company

Rare Kidney Diseases Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-kidney-diseases-global-market-report

Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/kidney-disease-global-market-report

Chronic Kidney Disease Market Report 2026

https://www.thebusinessresearchcompany.com/report/chronic-kidney-disease-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795